PropertyValue
?:abstract
  • There is currently no approved pharmaceutical product for the treatment of COVID-19. However, antibiotics are currently being used for the management of COVID-19 patients in many settings either treat to co-infections or for the treatment of COVID-19 itself. In this commentary, we highlight that the increased rates of antimicrobial prescribing for COVID-19 patients could further worsen the burden of antimicrobial resistance (AMR). We also highlight that though AMR is a global threat, Africa tends to suffer most from the consequences. We, therefore, call on African countries not to lose sight of the possible implications of the treatment of COVID-19 on AMR and a need to redouble efforts towards the fight against AMR while dealing with the pandemic.
is ?:annotates of
?:creator
?:doi
  • 10.11604/pamj.supp.2020.35.23713
?:doi
?:journal
  • Pan_Afr_Med_J
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/a953e06477682e8a4a3e4629b9e65f302f4d60dc.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7687464.xml.json
?:pmcid
?:pmid
?:pmid
  • 33282074.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • Treatment of COVID-19: implications for antimicrobial resistance in Africa
?:type
?:year
  • 2020-07-20

Metadata

Anon_0  
expand all